LBA5 Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1
2024 · Annals of Oncology · 4 citations
https://doi.org/10.1016/j.annonc.2024.10.642
E
E.F. Smit
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
7
Papers
24
Citations
2
h-index
1
i10-index
E.F. Smit is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Chronic Myeloid Leukemia Treatments & Lung Cancer Research Studies. The author has an h-index of 2, co-authored 6 publications.
Papers by this author
worksLBA74 Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1
2025 · Annals of Oncology · 2 citations
https://doi.org/10.1016/j.annonc.2025.09.088
PT2.12.03 Zongertinib in Patients With Previously Treated HER2-Mutant NSCLC and Brain Metastases at Baseline: Beamion LUNG-1
2025 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/j.jtho.2025.09.1159
1995P Treatment (Tx) sequencing of tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC): Outcomes from ≥3 years follow-up of the VISION study
2025 · Annals of Oncology · 0 citations
https://doi.org/10.1016/j.annonc.2025.08.2619
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat